Cody Sherrin, OD
Corneal and Contact Management · York, PANPI 1790409522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 34.1% of the total. Reporting peaked in 2024 at $1,180 and has fallen 51.0% since, to $579 in 2025. Among corneal and contact management clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $36.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Sun Pharmaceutical Industries Inc.$679
- Oyster Point Pharma, Inc.$210
- Tarsus Pharmaceuticals, Inc.$190
- Eyevance Pharmaceuticals LLC$159
- Alcon$139
- plus $572 from 8 others
What the payments were for
- Food & beverage$2,956100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 26 | $1,008 |
| Sun Pharmaceutical Industries Inc. | 25 | $679 |
| Oyster Point Pharma, Inc. | 8 | $210 |
| Tarsus Pharmaceuticals, Inc. | 3 | $190 |
| Eyevance Pharmaceuticals LLC | 2 | $159 |
| Alcon | 3 | $139 |
| Dompe US, Inc. | 4 | $114 |
| Amgen | 1 | $100 |
| Coopervision Inc. | 2 | $96 |
| Glaukos Corporation | 1 | $87 |
| AbbVie | 3 | $70 |
| Rxsight Inc | 2 | $69 |
| Harrow Eye, LLC | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$375
- ALDEN SCLERAL ZENLENS$240
- Tobradex ST$149
- TYRVAYA$100
- TEPEZZA$100
- MIEBO$100
- XIIDRA$100
How this compares
$2,956 in reported general payments places this provider in the 95th percentile of 43 corneal and contact management providers in Pennsylvania.
See all corneal and contact management providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 21 | $20,418 |
| RestasisCyclosporine | 15 | $10,498 |
| TyrvayaVarenicline Tartrate | 14 | $8,891 |
| Prednisolone Acetate | 90 | $4,588 |
| ValacyclovirValacyclovir Hcl | 47 | $2,669 |
| Fluorometholone | 26 | $2,083 |
| Difluprednate | 14 | $994 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $784 |
| Latanoprost | 27 | $473 |
| ErythromycinErythromycin Base | 40 | $464 |
| MoxifloxacinMoxifloxacin Hcl | 31 | $368 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $313 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $266 |
| Brimonidine Tartrate | 17 | $238 |
| Timolol Maleate | 17 | $198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $1,008 | $20,41821 claims |
| AbbVieRestasis | $70 | $10,49815 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $210 | $8,89114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 corneal and contact management providers in Pennsylvania.
Other corneal and contact management in York
- Russell GroveYork$34
- David PritzkerYork$27
- Monika MarczakMcMurray$6K
- John BoyleScranton$5K
- Mary NguyenSpringfield$2K
- Lowell LebovitzPittsburgh$2K
- Sandy JohnPlymouth Meeting$2K
- Irene MustenPhiladelphia$2K
- James CimbakHorsham$2K
- David CsonkaPittsburgh$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.